NASDAQ:AKBA Akebia Therapeutics (AKBA) Stock Forecast, Price & News $1.15 -0.02 (-1.71%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$1.14▼$1.2150-Day Range$1.13▼$1.8452-Week Range$0.24▼$1.84Volume1.16 million shsAverage Volume1.90 million shsMarket Capitalization$216.56 millionP/E RatioN/ADividend YieldN/APrice Target$3.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Akebia Therapeutics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside226.1% Upside$3.75 Price TargetShort InterestBearish3.84% of Shares Sold ShortDividend StrengthN/ASustainability-1.35Upright™ Environmental ScoreNews Sentiment0.56Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.34) to ($0.26) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.03 out of 5 starsMedical Sector608th out of 976 stocksPharmaceutical Preparations Industry286th out of 454 stocks 3.5 Analyst's Opinion Consensus RatingAkebia Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.75, Akebia Therapeutics has a forecasted upside of 226.1% from its current price of $1.15.Amount of Analyst CoverageAkebia Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted3.84% of the outstanding shares of Akebia Therapeutics have been sold short.Short Interest Ratio / Days to CoverAkebia Therapeutics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in Akebia Therapeutics has recently increased by 24.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAkebia Therapeutics does not currently pay a dividend.Dividend GrowthAkebia Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAkebia Therapeutics has received a 55.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Various other types of medication (V)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Akebia Therapeutics is -1.35. Previous Next 2.5 News and Social Media Coverage News SentimentAkebia Therapeutics has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Akebia Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 13 people have searched for AKBA on MarketBeat in the last 30 days. This is a decrease of -43% compared to the previous 30 days.MarketBeat Follows10 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Akebia Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.84% of the stock of Akebia Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 27.04% of the stock of Akebia Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.34) to ($0.26) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Akebia Therapeutics is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Akebia Therapeutics is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAkebia Therapeutics has a P/B Ratio of 38.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Akebia Therapeutics (NASDAQ:AKBA) StockAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Read More AKBA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AKBA Stock News HeadlinesSeptember 27, 2023 | markets.businessinsider.comPositive Prospects for Akebia Therapeutics: Buy Rating Upheld Amidst Drug Approval & Global Launch PreparationsSeptember 26, 2023 | finance.yahoo.comAkebia Announces Approval of Vafseo® (vadadustat) in Australia and Provides Commercial UpdateSeptember 28, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.September 26, 2023 | americanbankingnews.comAkebia Therapeutics (NASDAQ:AKBA) Shares Pass Below Fifty Day Moving Average of $1.34September 1, 2023 | msn.comAkebia Therapeutics (AKBA) Price Target Increased by 29.17% to 3.95August 28, 2023 | msn.comHC Wainwright & Co. Upgrades Akebia Therapeutics (AKBA)August 28, 2023 | msn.comAnalyst Highly Confident In Akebia Therapeutics' Kidney Disease-Associated Anemia Drug, Stock SoarsAugust 28, 2023 | finance.yahoo.comAkebia Therapeutics, Inc. (NASDAQ:AKBA) Q2 2023 Earnings Call TranscriptSeptember 28, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.August 28, 2023 | finance.yahoo.comUnveiling Akebia Therapeutics (AKBA)'s Value: Is It Really Priced Right? A Comprehensive GuideAugust 28, 2023 | finance.yahoo.comIs Akebia Therapeutics Inc (AKBA) Set to Underperform? Analyzing the Factors Limiting GrowthAugust 26, 2023 | seekingalpha.comAKBA Akebia Therapeutics, Inc.August 26, 2023 | seekingalpha.comAkebia Therapeutics, Inc. (AKBA) Q2 2023 Earnings Call TranscriptAugust 26, 2023 | finance.yahoo.comQ2 2023 Akebia Therapeutics Inc Earnings CallAugust 25, 2023 | finance.yahoo.comAkebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue EstimatesAugust 25, 2023 | markets.businessinsider.comAkebia Therapeutics Posts Loss In Q2; Net Product Revenue Down 2.5%August 25, 2023 | finance.yahoo.comAkebia Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business HighlightsAugust 24, 2023 | markets.businessinsider.comAkebia Therapeutics Expects To Resubmit NDA For Vadadustat NDA In Q3August 24, 2023 | finance.yahoo.comAkebia Therapeutics Expects to Resubmit Vadadustat NDA in Third Quarter 2023August 23, 2023 | finance.yahoo.comAkebia Therapeutics to Report Second Quarter Financial Results and Discuss Recent Business HighlightsAugust 17, 2023 | finance.yahoo.comAkebia Therapeutics to Report Second Quarter Financial Results by August 25, 2023August 11, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Hold Rating on Akebia Therapeutics (AKBA)August 11, 2023 | finance.yahoo.comAkebia Therapeutics Provides Update on Form 10-Q FilingAugust 8, 2023 | msn.comLyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue EstimatesAugust 4, 2023 | msn.comAkebia Therapeutics: Take Profits Before Second Quarter ReportJuly 26, 2023 | finance.yahoo.comAre Medical Stocks Lagging InMode (INMD) This Year?July 19, 2023 | finance.yahoo.comAkebia Therapeutics to Present at the H.C. Wainwright Kidney ConferenceSee More Headlines Receive AKBA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKBA Company Calendar Last Earnings8/25/2023Today9/27/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AKBA CUSIPN/A CIK1517022 Webwww.akebia.com Phone(617) 871-2098Fax617-871-2099Employees204Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.75 High Stock Price Forecast$3.75 Low Stock Price Forecast$3.75 Forecasted Upside/Downside+220.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-94,230,000.00 Net Margins-48.25% Pretax Margin-49.16% Return on Equity-249.60% Return on Assets-29.28% Debt Debt-to-Equity Ratio6.52 Current Ratio1.28 Quick Ratio1.06 Sales & Book Value Annual Sales$292.60 million Price / Sales0.75 Cash FlowN/A Price / Cash FlowN/A Book Value$0.03 per share Price / Book39.00Miscellaneous Outstanding Shares188,310,000Free Float181,083,000Market Cap$220.32 million OptionableOptionable Beta0.83 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. John P. Butler MBA (Age 59)CEO, Pres & Director Comp: $1.29MMr. Michel Dahan (Age 44)Sr. VP & COO Comp: $734.73kMs. Nicole R. Hadas J.D. (Age 50)Sr. VP, Chief Legal Officer & Sec. Comp: $687.38kDr. Steven Keith Burke (Age 62)Sr. VP of R&D and Chief Medical Officer Comp: $766.57kMs. Ellen E. Snow CPA (Age 51)CGMA, Sr. VP, CFO, Treasurer & Principal Accounting Officer Tracey VetterickVP of Portfolio Strategy & Corp. Admin.Mercedes CarrascoDirector of Corp. CommunicationsMr. Douglas Jermasek M.B.A. (Age 62)VP of Marketing & Strategy Ms. Meredith BowmanSr. VP of PeopleMs. Kimberly GarkoSr. VP of Quality, Manufacturing & Pharmaceutical Devel.More ExecutivesKey CompetitorsRenovaro BiosciencesNASDAQ:RENBImmuneeringNASDAQ:IMRXVerastemNASDAQ:VSTMGracell BiotechnologiesNASDAQ:GRCLKamadaNASDAQ:KMDAView All CompetitorsInsiders & InstitutionsWolverine Trading LLCBought 14,600 shares on 8/23/2023Ownership: 0.000%XTX Topco LtdBought 339,367 shares on 8/15/2023Ownership: 0.183%Citadel Advisors LLCBought 200 shares on 8/15/2023Ownership: 0.000%State Street CorpSold 66,786 shares on 8/14/2023Ownership: 0.337%State of WyomingBought 48,207 shares on 8/14/2023Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions AKBA Stock - Frequently Asked Questions Should I buy or sell Akebia Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AKBA shares. View AKBA analyst ratings or view top-rated stocks. What is Akebia Therapeutics' stock price forecast for 2023? 2 brokerages have issued 1 year target prices for Akebia Therapeutics' stock. Their AKBA share price forecasts range from $3.75 to $3.75. On average, they expect the company's share price to reach $3.75 in the next twelve months. This suggests a possible upside of 220.5% from the stock's current price. View analysts price targets for AKBA or view top-rated stocks among Wall Street analysts. How have AKBA shares performed in 2023? Akebia Therapeutics' stock was trading at $0.5770 at the beginning of the year. Since then, AKBA shares have increased by 102.8% and is now trading at $1.17. View the best growth stocks for 2023 here. Are investors shorting Akebia Therapeutics? Akebia Therapeutics saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 7,230,000 shares, an increase of 24.4% from the August 31st total of 5,810,000 shares. Based on an average daily trading volume, of 1,760,000 shares, the short-interest ratio is currently 4.1 days. View Akebia Therapeutics' Short Interest. When is Akebia Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our AKBA earnings forecast. How were Akebia Therapeutics' earnings last quarter? Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its quarterly earnings data on Friday, August, 25th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.03. The biopharmaceutical company had revenue of $56.38 million for the quarter, compared to the consensus estimate of $59.10 million. Akebia Therapeutics had a negative net margin of 48.25% and a negative trailing twelve-month return on equity of 249.60%. During the same quarter in the previous year, the firm earned $0.23 earnings per share. What ETF holds Akebia Therapeutics' stock ? Invesco Nasdaq Future Gen 200 ETF holds 33,325 shares of AKBA stock, representing 0.72% of its portfolio. What is John Butler's approval rating as Akebia Therapeutics' CEO? 28 employees have rated Akebia Therapeutics Chief Executive Officer John Butler on Glassdoor.com. John Butler has an approval rating of 97% among the company's employees. This puts John Butler in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Akebia Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T). What is Akebia Therapeutics' stock symbol? Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA." Who are Akebia Therapeutics' major shareholders? Akebia Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Acadian Asset Management LLC (4.01%), Renaissance Technologies LLC (1.79%), BlackRock Inc. (1.47%), Geode Capital Management LLC (0.95%), Victory Capital Management Inc. (0.36%) and State Street Corp (0.34%). Insiders that own company stock include David A Spellman, John P Butler, Michel Dahan, Nicole R Hadas, Steven C Gilman, Steven C Gilman, Steven Keith Burke and Violetta Cotreau. View institutional ownership trends. How do I buy shares of Akebia Therapeutics? Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Akebia Therapeutics' stock price today? One share of AKBA stock can currently be purchased for approximately $1.17. How much money does Akebia Therapeutics make? Akebia Therapeutics (NASDAQ:AKBA) has a market capitalization of $220.32 million and generates $292.60 million in revenue each year. The biopharmaceutical company earns $-94,230,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. How many employees does Akebia Therapeutics have? The company employs 204 workers across the globe. How can I contact Akebia Therapeutics? Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The official website for the company is www.akebia.com. The biopharmaceutical company can be reached via phone at (617) 871-2098, via email at ir@akebia.com, or via fax at 617-871-2099. This page (NASDAQ:AKBA) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.